What is Boniva IV?
Boniva Injection, the first quarterly medication for the treatment of postmenopausal osteoporosis, is a member of the bisphosphonate class, which is the most frequently prescribed medicine for osteoporosis.1 It is administered by a healthcare professional once every three months. Boniva Injection, administered as a 15-30 second IV injection, will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements, including an inability to sit upright for 30 to 60 minutes and/or swallow a pill. Additionally, because Boniva IV will be administered by healthcare professionals, clinicians will have a greater awareness of patient compliance with therapy. Boniva IV was approved by the FDA based on results of the DIVA study (Dosing IntraVenous Administration), a clinical trial in 1,358 women with postmenopausal osteoporosis. Boniva IV will be available early 2006. The FDA approved once-monthly Boniva in March 2005 as the first once-a-month tablet for postmeno
